Alnylam launches digital tool for ATTR amyloidosis patientsAlnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to Share XAlnylam launches digital tool for ATTR amyloidosis patientshttps://pharmaphorum.com/news/alnylam-launches-digital-tool-for-aatr-amyloidosis-patients/
Novo Nordisk bulks up in rare diseases with $1.2bn Prothena dealDiabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition Share XNovo Nordisk bulks up in rare diseases with $1.2bn Prothena dealhttps://pharmaphorum.com/news/novo-nordisk-bulks-up-in-rare-diseases-with-1-2bn-prothena-deal/
Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drugThe first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the Share XIntellia, Regeneron ace first trial with ‘in vivo’ CRISPR drughttps://pharmaphorum.com/news/intellia-regeneron-ace-first-trial-with-in-vivo-crispr-drug/
Vyndaqel romps away in US, spurring earnings hike from PfizerPfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its Share XVyndaqel romps away in US, spurring earnings hike from Pfizerhttps://pharmaphorum.com/news/vyndaqel-romps-away-in-us-spurring-earnings-hike-from-pfizer/
Alnylam gears up for first RNAi therapeutic filing in 2017US biotech Alnylam says it could file its first product in 2017, a rare disease drug using what Share XAlnylam gears up for first RNAi therapeutic filing in 2017https://pharmaphorum.com/news/alnylam-gears-up-for-first-rnai-therapeutic-filing-in-2017/
